Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 72,314 |
|
|||||
| News | - | ||||||
| Day High | 5.40 | Low High |
|||||
| Day Low | 5.19 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Alector Inc | ALEC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.13 | 2.51% | 5.30 | 13:08:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.21 | 5.19 | 5.40 | 5.17 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,646 | 72,314 | $ 5.30 | $ 383,350 | - | 3.66 - 9.065 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:09:04 | 100 | $ 5.30 | USD |
Alector Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 502.68M | 95.75M | - | 97.06M | -130.39M | -1.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alector News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALEC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.64 | 5.64 | 4.945 | 5.14 | 430,646 | -0.34 | -6.03% |
| 1 Month | 6.03 | 6.25 | 4.945 | 5.78 | 594,948 | -0.73 | -12.11% |
| 3 Months | 6.20 | 7.5773 | 4.945 | 6.19 | 699,916 | -0.90 | -14.52% |
| 6 Months | 5.26 | 8.90 | 3.66 | 6.19 | 678,221 | 0.04 | 0.76% |
| 1 Year | 6.60 | 9.065 | 3.66 | 6.42 | 639,296 | -1.30 | -19.70% |
| 3 Years | 18.83 | 43.32 | 3.66 | 14.69 | 696,428 | -13.53 | -71.85% |
| 5 Years | 21.44 | 45.00 | 3.66 | 16.22 | 638,016 | -16.14 | -75.28% |
Alector Description
| Alector Inc is a clinical stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies which are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline product inlcude AL001, AL002, AL003, and AL101. |
